Issued 2026-08-13 at $6.90 · now $7.00 (2026-08-13, +1.4% since)
Based on its own history, a month from the 2026-08-13 close, AGEN has typically landed between $4.58 and $10.17 — a range of −33.6% to +47.4% from the issuance price $6.90.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,977 overlapping 1 month windows · 2006-09-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($6.90) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where AGEN has typically landed a month from the 2026-08-13 close of $6.9 — the range is history, not a prediction.
- now $7 (+1.4%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $6.48 (-6.1%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $5.45–$7.5
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.58–$10.17
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-07-16 | −74.1% | −74.1% | +0.2% |
| 2024-07-17 | −70.8% | −74.2% | +0.0% |
| 2024-07-15 | −69.8% | −69.8% | +13.7% |
| 3 best | |||
| 2009-05-01 | +267.8% | −25.6% | +267.8% |
| 2009-05-26 | +246.2% | +0.0% | +394.3% |
| 2009-05-07 | +228.2% | −23.9% | +276.1% |
4,977 overlapping windows · 2006-09-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2027 — Trial primary completion: Phase 2 primary completion: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (source, as of 2026-08-14)
- February 2028 — Trial primary completion: Phase 2 primary completion: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.